London, June 19, 2026, 13:16 BST
- Reckitt traded at 4,616 pence, down 0.7%, after touching a session low of 4,613 pence.
- The FTSE 100 fell 0.3% as cancelled U.S.-Iran talks restrained risk appetite.
- Reckitt has completed its £1 billion share buyback. Half-year results are scheduled for July 29.
Reckitt Benckiser Group shares edged lower in London on Friday, slipping towards the bottom of their 4,613-4,659 pence trading range. The decline was modest, but slightly steeper than the broader market’s fall.
There was no fresh trading statement behind the move. The London Stock Exchange’s company feed showed Reckitt’s newest regulatory notices were issued on June 16, suggesting Friday’s dealing was more about investor positioning than a new change in operations.
Reckitt confirmed on Tuesday that it had finished the third and final tranche of the £1 billion buyback announced last July. The company purchased 11.1 million shares in that tranche at an average £48.55 each. A buyback is when a company repurchases its own shares, creating regular demand for the stock; its completion removes that mechanical support, though there is no evidence it caused Friday’s decline.
The more material issue is costs. Chief Executive Kris Licht said this week that companies were “really just at the beginning” of seeing geopolitical disruption and tariffs feed through to consumers, adding that Reckitt’s input prices could be affected over the next year. That leaves investors weighing how much of any increase can be offset through pricing, savings or product mix. Reuters
The operating base is already uneven. Reckitt reported first-quarter like-for-like net revenue growth of 1.3% in its core business, rising to 3.1% when seasonal over-the-counter medicines were excluded. Like-for-like growth strips out currency movements and changes in the businesses owned. The company kept its full-year guidance unchanged.
Still, the 1.3% result missed the 2.9% analyst consensus, while Reckitt expects first-half margins to be about 200 basis points lower than a year earlier. One basis point is one-hundredth of a percentage point. Harsharan Mann, consumer-sector hub lead at shareholder Aviva Investors, described the quarter as showing “broad-based muted growth.” Reuters
Peer trading offered a mixed signal. Unilever fell about 0.6%, while consumer-health group Haleon added roughly 0.1%. That suggests part of Reckitt’s move reflected a soft defensive-consumer trade, although company-specific questions around margins and the buyback remain.
There was some relief on Reckitt’s largest legal overhang. An Illinois appeals court reversed a $60 million verdict against its Mead Johnson infant-formula unit and ordered a new trial, ruling that jurors received incorrect instructions. But nearly 1,000 similar lawsuits have been filed against Mead Johnson and Abbott over necrotizing enterocolitis, a serious bowel disease that mainly affects premature infants. The decision reduced one liability; it did not settle the wider litigation.
But the downside case remains plain. Persistently high commodity and transport costs, another weak season for cold-and-flu products, or adverse formula rulings could squeeze earnings and test guidance. Stronger emerging-market sales provide the main counterweight: Reckitt’s fourth-quarter revenue in those markets rose 17.2%, while Europe declined 4.5%.
Friday’s decline is too small to establish a new trend. It does show that, with the buyback finished, investors are waiting for operating evidence rather than another capital-return signal. The next scheduled test is Reckitt’s half-year presentation on July 29 at 08:30 BST.
